Overview
The retrospective cohort study INFINITY will be an instrument to analyze the current practice of precision oncology in the real-world setting. It will provide insight into real-world biomarker-directed treatment of cancer patients not eligible for standard therapies. The study will retrospectively collect medical records' data of patients who received a targeted treatment based on a potentially actionable alteration or biomarker identified by molecular diagnostics. Data of deceased patients will be included. The study will analyze how molecular test results guided clinical decision making. The compiled treatment and outcome data will be a valuable resource to analyze the use and effectiveness of targeted therapy approaches in biomarker-defined and entity-defined subpopulations of cancer patients. These signals might generate new insights and foster progress of targeted cancer treatment. The associated biomarker profiling module aims to set up a decentral biobank for future research on molecular alterations or central re-testing.
Eligibility
Inclusion Criteria:
- Advanced hematologic malignancy or solid tumor not eligible for standard therapy options (i.e. without further treatment options based on drugs approved for the specific indication at time of enrollment)
- Started or completed at the documenting study site a non-standard, targeted therapy based on an actionable alteration or biomarker identified by molecular diagnostics
- Start of the non-standard therapy no longer than 24 months before first data collection
- Age 18 years
- Signed and dated informed consent form (only if patient is alive at time of data entry into the project; not applicable for inclusion of deceased patients' data)
Exclusion Criteria:
- None